Log in or Sign up for Free to view tailored content for your specialty!
Ophthalmic Business News
Oral geographic atrophy treatment misses primary endpoint in phase 3 study
Oral gildeuretinol acetate did not meet the primary endpoint of geographic atrophy lesion growth rate in a phase 3 study, according to a press release from Alkeus Pharmaceuticals.
Live from Women in Ophthalmology: Discussing residency programs
On this episode, Laura Enyedi, MD, is live from the Women in Ophthalmology meeting with Pratap Challa, MD, Fasika Woreta, MD, Jennifer Lindsey, MD, and Annie Wishna, MD, discussing residency programs.
FDA grants orphan drug designation for ATSN-201 for X-linked retinoschisis
ATSN-201 received orphan drug designation from the FDA for the treatment of X-linked retinoschisis, according to a press release from Atsena Therapeutics.
Log in or Sign up for Free to view tailored content for your specialty!
ANI Pharmaceuticals completes acquisition of Alimera Sciences
ANI Pharmaceuticals finalized its acquisition of Alimera Sciences, according to a press release.
Start early to leverage the power of compound interest
Saving money at an early age is perhaps the simplest and one of the most effective methods to accumulate wealth.
Sonoma, EMC to co-market eye care product line
Sonoma Pharmaceuticals and EMC Pharma have entered into a co-marketing agreement to expand their eye care product lines, according to a press release.
FDA clears OCTA on robotic Maestro2 color fundus camera system
The FDA granted 510(k) clearance for OCT angiography on the robotic Maestro2 OCT color fundus camera system, according to a press release from Topcon Healthcare.
Veligrotug for treatment of thyroid eye disease meets endpoints in phase 3 trial
Viridian Therapeutics reported positive topline data from the phase 3 THRIVE clinical trial of veligrotug for the treatment of active thyroid eye disease.
Understand stock and bond index funds for slow, steady growth
One important investment vehicle to understand when working toward slow and steady growth is the index fund.
First subjects dosed in phase 3 trial of phentolamine ophthalmic solution for presbyopia
Ocuphire Pharma has dosed the first participants in the VEGA-3 phase 3 clinical trial investigating phentolamine ophthalmic solution 0.75% for the treatment of presbyopia, according to a press release.
-
Headline News
Burnout, withdrawal remain ‘alarmingly high’ among physicians and residents
September 17, 20242 min read -
Headline News
Over one-third of adults not planning on receiving recommended vaccines this fall
September 18, 20242 min read -
Headline News
Popular home BP devices unable to provide accurate readings for millions due to sizing
September 19, 20242 min read
-
Headline News
Burnout, withdrawal remain ‘alarmingly high’ among physicians and residents
September 17, 20242 min read -
Headline News
Over one-third of adults not planning on receiving recommended vaccines this fall
September 18, 20242 min read -
Headline News
Popular home BP devices unable to provide accurate readings for millions due to sizing
September 19, 20242 min read